Atrial FibrillationPhase 3ACT INCT00468767
Phase III Tolerance and Efficacy Study of RSD1235 in Patients With Atrial Fibrillation
A Phase 3 study testing Vernakalant Injection 20 mg/mL in people with Atrial Fibrillation, run by Advanz Pharma at 49 sites in 4 countries.
Trial summary
This study is being conducted to demonstrate the effectiveness of RSD1235 in the conversion of atrial fibrillation to sinus rhythm. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Atrial Fibrillation
- What is being tested?
- Vernakalant Injection 20 mg/mL
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 356 participants
- Where
- 49 sitesin 4 countries
- Study dates
- Aug 2003to Nov 2004
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- 18 years of age or older;
- Have an atrial arrhythmia with symptoms that has been sustained for greater than 3 hours and up to 45 days.
- Have adequate anticoagulant therapy.
Who cannot join
- Have a QRS > 0.14 seconds unless patient has pacemaker or uncorrected QT > 0.440 seconds as measured on a 12-lead ECG.
- Have serious diseases/illnesses that could interfere with the conduct or validity of the study or compromise patient safety.
- Have received intravenous Class I or Class III antiarrhythmic drugs or intravenous amiodarone within 24 hours prior to dosing.
Trial locations and contacts
49 sites in 4 countries.
49 sites in 4 countries
Denmark20 sites
Aalborg University
Aalborg
Århus Amtssygehus, Med. kardiologisk
Aarhus
Amager Hospital, Med. Center
Copenhagen
H:S Bispebjerg Hospital
Copenhagen
Helsingor Sygehus, Kardiovaskulært
Elsinore
Centralsygehuset Esbjerg Varde
Esbjerg
Fredericia Sygehus
Fredericia
Frederikssund Sygehus
Frederikssund
Glostrup Amtssygehus
Glostrup Municipality
Haderslev Sygehus, Kardiologisk Laboratorium
Haderslev
Gentofte Amtssygehus
Hellerup
Herlev Amtssygehus, Kardiologisk
Herlev
Hillerod Sygehus, Medicinsk
Hillerød
Sygehus Vendsyssel Hjorring
Hjørring
Holstebro centralsygehus
Holstebro
Horsens Sygehus
Horsens
Hvidovre Hospital, Kardiologisk
Hvidovre
Roskilde Amts Sygehus Køge
Køge
Kolding Sygehus, Kardiologisk ambulatorium
Kolding
Sygehus Fyn Svendborg
Svendborg
Canada12 sites
Heart Health Institute, Rockyview General Hospital
Calgary, Alberta, T2E 7C5
University of Calgary
Calgary, Alberta, T2N 4N1
University of Alberta Hospital
Edmonton, Alberta, T6G 2B7
Hamilton Health Sciences, Hamilton General Hospital
Hamilton, Ontario, L8L 2X2
Institut de Cardiologie de Montreal
Montreal, Quebec, H1T 1C8
Hopital Notre-Dame du CHUM
Montreal, Quebec, H2L 4M1
CHUM-Hotel-Dieu de Montreal
Montreal, Quebec, H2W 1T8
Ottawa Hospitals (Civic & General)
Ottawa, Ontario, K1Y 4E9
Institute de Cardiologie de Quebec, Hopital Laval
Ste Foy, Quebec, G1V 4G5
Centre Hospitalier LeGardeur
Terrebonne, Quebec, J6V 2H2
Sunnybrook Health Sciences Centre, Emergency Medicine Research Program
Toronto, Ontario, M4N 3M5
Cardiac Arrhythmia Trials
Victoria, British Columbia, V8R 4R2
United States11 sites
Cardiac Arrhythmia Service, Massachusetts General Hospital
Boston, Massachusetts, 02459
Thoracic and Cardiovascular Institute
Lansing, Michigan, 48910
University of California
Los Angeles, California, 90073
Marshfield Clinic
Marshfield, Wisconsin, 54449
Florida Heart Institute
Orlando, Florida, 32803
Oregon Health & Science University
Portland, Oregon, 97201
Medical College of Virginia
Richmond, Virginia, 23219
McGuire VA Medical Center
Richmond, Virginia, 23249
Regional Cardiology Associates
Sacramento, California, 95819
James Haley VA Hospital
Tampa, Florida, 33612
Main Line Health Heart Center
Wynnewood, Pennsylvania, 19096
Sweden6 sites
Universitetssjukhuset MAS
Malmö
Universitetssjukhuset, Molndal
Mölndal
Universityetssjukhuset, Orebro
Örebro
Danderyds sjukhus
Stockholm
Akademiska Sjukhuset, Uppsala
Uppsala
Centrallasarettet, Vasteras
Västerås
About this study
Official title: A Phase III Prospective, Randomized, Double-Blind, Placebo-Controlled, Multi-Centred Tolerance and Efficacy Study of RSD1235 in Patients With Atrial Fibrillation
This study is being conducted to demonstrate the effectiveness of RSD1235 in the conversion of atrial fibrillation to sinus rhythm.
Read the detailed description
There are approximately 2 million reported prevalent cases of atrial fibrillation (AF) and atrial flutter in the United States (Heart Disease \& Stroke Statistics - 2003 Update, AHA). These arrhythmias may be occasional or sustained. While not directly fatal, these arrhythmias cause discomfort and can lead to stroke or congestive heart failure.
This Phase III trial is Cardiome's first pivotal study with RSD1235. The study seeks to confirm the findings of the Phase II proof-of-concept through demonstration of RSD1235's abilities to convert AF to sinus rhythm. The patient population will include recent onset AF (AF duration of 3 hours to 7 days) and patients with longer AF duration.
This is a double-blind, placebo-controlled, randomized study in patients with AF; stratification will be based on duration of AF. Treatment will be considered successful if there is a treatment-induced conversion of atrial arrhythmia to sinus rhythm for a minimum of 1-minute by Hour 1.5 (Time 0 = start of first infusion). All patients will be evaluated for safety.
- Conditions
- Atrial Fibrillation
- Being tested
- Vernakalant Injection 20 mg/mL
- Keywords
- Atrial fibrillation, RSD1235, Atrial fibrillation of 3 hours to 7 days duration., Atrial fibrillation of 3 hours to 45 days duration.
- Medical subject headings
- Atrial Fibrillation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Vernakalant Injection 20 mg/mLDrug
Also called RSD1235; Vernakalant; Vernakalant Injection; Vernakalant (iv)
| Study group | Role | What they receive |
|---|---|---|
| 1 | Experimental | Atrial fibrillation (AF) duration of 3 hours to 7 days. Receives: Drug: Vernakalant Injection 20 mg/mL |
| 2 | Experimental | AF duration of >7 days to <45 days Receives: Drug: Vernakalant Injection 20 mg/mL |
What is being measured
The primary outcome is the main question the study is designed to answer.
To demonstrate the effectiveness of RSD1235 in the conversion of atrial fibrillation to sinus rhythm.
Measured: The proportion of patients with atrial fibrillation (AF) of 3 hours to 7 days duration who have treatment-induced conversion of AF to sinus rhythm for a minimum duration of one minute in the first 90 minutes after the first exposure to study treatment.
Secondary outcomes (1)
To assess the safety of RSD1235 in this patient population.
Measured: The proportion of patients with AF of 3 hours to 45 days duration who have treatment-induced conversion of AF to sinus rhythm for a minimum duration of one minute in the first 90 minutes after the first exposure to study treatment.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 May 2007 (estimated)
- Study startAug 2003
- Primary completionNov 2004
- Study completionNov 2004
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Atrial FibrillationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 356 participants (actual)
Sponsor and investigators
- Lead sponsor
- Advanz Pharma
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Astellas Pharma US, Inc.
- Investigators
- Sheila Grant, MBA, Study director, Advanz Pharma
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00468767
- Sponsor's protocol ID
- 1235-0703
- Acronym
- ACT I
- Status last verified
- Mar 2008
- First submitted
- 1 May 2007
- Last updated
- 2 Apr 2008
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Stiell IG, Dickinson G, Butterfield NN, Clement CM, Perry JJ, Vaillancourt C, Calder LA. Vernakalant hydrochloride: A novel atrial-selective agent for the cardioversion of recent-onset atrial fibrillation in the emergency department. Acad Emerg Med. 2010 Nov;17(11):1175-82. doi: 10.1111/j.1553-2712.2010.00915.x.
PubMed 21175515Roy D, Pratt CM, Torp-Pedersen C, Wyse DG, Toft E, Juul-Moller S, Nielsen T, Rasmussen SL, Stiell IG, Coutu B, Ip JH, Pritchett EL, Camm AJ; Atrial Arrhythmia Conversion Trial Investigators. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation. 2008 Mar 25;117(12):1518-25. doi: 10.1161/CIRCULATIONAHA.107.723866. Epub 2008 Mar 10.
PubMed 18332267
Study at a glance
From the registry record, last updated by the sponsor on 2 Apr 2008. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase III Prospective, Randomized, Double-Blind, Placebo-Controlled, Multi-Centred Tolerance and Efficacy Study of RSD1235 in Patients With Atrial Fibrillation
- ClinicalTrials.gov ID
- NCT00468767
- Acronym / sponsor ID
- ACT I / 1235-0703
- Conditions
- Atrial Fibrillation
- Keywords
- Atrial fibrillation, RSD1235, Atrial fibrillation of 3 hours to 7 days duration., Atrial fibrillation of 3 hours to 45 days duration.
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 356 participants (actual)
- Lead sponsor
- Advanz PharmaIndustry (pharma, biotech, devices)
- Collaborators
- Astellas Pharma US, Inc.
- Study start
- Aug 2003
- Primary completion
- Nov 2004 (actual)
- Study completion
- Nov 2004 (actual)
- First posted
- 3 May 2007 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is being conducted to demonstrate the effectiveness of RSD1235 in the conversion of atrial fibrillation to sinus rhythm.
Detailed description
There are approximately 2 million reported prevalent cases of atrial fibrillation (AF) and atrial flutter in the United States (Heart Disease \& Stroke Statistics - 2003 Update, AHA). These arrhythmias may be occasional or sustained. While not directly fatal, these arrhythmias cause discomfort and can lead to stroke or congestive heart failure.
This Phase III trial is Cardiome's first pivotal study with RSD1235. The study seeks to confirm the findings of the Phase II proof-of-concept through demonstration of RSD1235's abilities to convert AF to sinus rhythm. The patient population will include recent onset AF (AF duration of 3 hours to 7 days) and patients with longer AF duration.
This is a double-blind, placebo-controlled, randomized study in patients with AF; stratification will be based on duration of AF. Treatment will be considered successful if there is a treatment-induced conversion of atrial arrhythmia to sinus rhythm for a minimum of 1-minute by Hour 1.5 (Time 0 = start of first infusion). All patients will be evaluated for safety.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| 1 | Experimental | Drug: Vernakalant Injection 20 mg/mLAtrial fibrillation (AF) duration of 3 hours to 7 days. |
| 2 | Experimental | Drug: Vernakalant Injection 20 mg/mLAF duration of >7 days to <45 days |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- 18 years of age or older;
- Have an atrial arrhythmia with symptoms that has been sustained for greater than 3 hours and up to 45 days.
- Have adequate anticoagulant therapy.
Key exclusion criteria (3 listed)
- Have a QRS > 0.14 seconds unless patient has pacemaker or uncorrected QT > 0.440 seconds as measured on a 12-lead ECG.
- Have serious diseases/illnesses that could interfere with the conduct or validity of the study or compromise patient safety.
- Have received intravenous Class I or Class III antiarrhythmic drugs or intravenous amiodarone within 24 hours prior to dosing.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Vernakalant Injection 20 mg/mLAlso: RSD1235; Vernakalant; Vernakalant Injection; Vernakalant (iv) | Drug | 1, 2 |
Primary outcome
To demonstrate the effectiveness of RSD1235 in the conversion of atrial fibrillation to sinus rhythm.
Time frame: The proportion of patients with atrial fibrillation (AF) of 3 hours to 7 days duration who have treatment-induced conversion of AF to sinus rhythm for a minimum duration of one minute in the first 90 minutes after the first exposure to study treatment.
1 secondary outcome
To assess the safety of RSD1235 in this patient population.
Time frame: The proportion of patients with AF of 3 hours to 45 days duration who have treatment-induced conversion of AF to sinus rhythm for a minimum duration of one minute in the first 90 minutes after the first exposure to study treatment.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Apr 2008.
- Derived from this study: PubMed 21175515Stiell IG, Dickinson G, Butterfield NN, Clement CM, Perry JJ, Vaillancourt C, Calder LA. Vernakalant hydrochloride: A novel atrial-selective agent for the cardioversion of recent-onset atrial fibrillation in the emergency department. Acad Emerg Med. 2010 Nov;17(11):1175-82. doi: 10.1111/j.1553-2712.2010.00915.x.
- Derived from this study: PubMed 18332267Roy D, Pratt CM, Torp-Pedersen C, Wyse DG, Toft E, Juul-Moller S, Nielsen T, Rasmussen SL, Stiell IG, Coutu B, Ip JH, Pritchett EL, Camm AJ; Atrial Arrhythmia Conversion Trial Investigators. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation. 2008 Mar 25;117(12):1518-25. doi: 10.1161/CIRCULATIONAHA.107.723866. Epub 2008 Mar 10.
Related trials for Atrial Fibrillation
Active, not recruiting
Horizon 360 Protocol for the Treatment of Paroxysmal Atrial Fibrillation With the Sphere-360™ Catheter and Affera™ Mapping and Ablation System (Horizon 360)
Paroxysmal AF
Active, not recruitingObservational study
Concomitant Left Atrial Appendage Closure and Pulsed Field Ablation-Asia
Concomitant Procedures, Atrial Fibrillation
Active, not recruiting
CONVERGE Post-Approval Study (PAS)
Chronic Atrial Fibrillation
Recruiting
Early Closure of Left Atrial Appendage for Patients With Atrial Fibrillation and Ischemic Stroke Despite Anticoagulation Therapy
Ischemic Stroke, Atrial Fibrillation
RecruitingPhase 2
Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
Atrial Fibrillation (AF)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Sheila Grant, MBA study director
Advanz Pharma
49 sites in 4 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Vernakalant Injection 20 mg/mL in people with Atrial Fibrillation, run by Advanz Pharma at 49 sites in 4 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Apr 2008. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 49 sites in Denmark, Canada, United States, Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To demonstrate the effectiveness of RSD1235 in the conversion of atrial fibrillation to sinus rhythm. (time frame: The proportion of patients with atrial fibrillation (AF) of 3 hours to 7 days duration who have treatment-induced conversion of AF to sinus rhythm for a minimum duration of one minute in the first 90 minutes after the first exposure to study treatment.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00468767, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Apr 2008.